{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T14:48:52Z","timestamp":1785163732361,"version":"3.55.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1097\/igc.0b013e318234f833","type":"journal-article","created":{"date-parts":[[2011,11,11]],"date-time":"2011-11-11T13:10:12Z","timestamp":1321017012000},"page":"232-237","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Intraperitoneal Chemotherapy for Recurrent Epithelial Ovarian Cancer Is Feasible With High Completion Rates, Low Complications, and Acceptable Patient Outcomes"],"prefix":"10.1016","volume":"22","author":[{"given":"Malgorzata E.","family":"Skaznik-Wikiel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie L.","family":"Lesnock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C.","family":"McBee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushil","family":"Beriwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin K.","family":"Zorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas C.","family":"Krivak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1097\/IGC.0b013e318234f833_bb0005","first-page":"277","article-title":"Cancer statistics, 2010","volume":"60","author":"Jemal","year":"2010","journal-title":"CA Cancer J Clin."},{"key":"10.1097\/IGC.0b013e318234f833_bb0010","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/S0002-9378(94)70090-7","article-title":"The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma","volume":"170","author":"Hoskins","year":"1994","journal-title":"Am J Obstet Gynecol."},{"key":"10.1097\/IGC.0b013e318234f833_bb0015","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","article-title":"Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer","volume":"335","author":"Alberts","year":"1996","journal-title":"N Engl J Med."},{"key":"10.1097\/IGC.0b013e318234f833_bb0020","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","volume":"19","author":"Markman","year":"2001","journal-title":"J Clin Oncol."},{"key":"10.1097\/IGC.0b013e318234f833_bb0025","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N Engl J Med."},{"key":"10.1097\/IGC.0b013e318234f833_bb0030","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0090-8258(03)00474-8","article-title":"Long-term survival with consolidation intraperitoneal chemotherapy for patients with advanced ovarian cancer with pathological complete remission","volume":"91","author":"Tournigand","year":"2003","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0b013e318234f833_bb0035","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/IGC.0b013e31819bdc7e","article-title":"Survival following second-line intraperitoneal therapy for the treatment of epithelial ovarian cancer: the Gynecologic Oncology Group experience","volume":"19","author":"Markman","year":"2009","journal-title":"Int J Gynecol Cancer."},{"key":"10.1097\/IGC.0b013e318234f833_bb0040","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1200\/JCO.2002.20.5.1248","article-title":"Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis","volume":"20","author":"Bristow","year":"2002","journal-title":"J Clin Oncol."},{"key":"10.1097\/IGC.0b013e318234f833_bb0045","first-page":"735","article-title":"Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs cisplatin and paclitaxel (GOG158) and an update on GOG0182-ICON5","volume":"13","author":"Bookman","year":"2003","journal-title":"Int J Gyneol Cancer."},{"key":"10.1097\/IGC.0b013e318234f833_bb0050","doi-asserted-by":"crossref","first-page":"845","DOI":"10.7326\/0003-4819-97-6-845","article-title":"Intraperitoneal cisplatin with systemic thiosulfate protection","volume":"97","author":"Howell","year":"1982","journal-title":"Ann Intern Med."},{"key":"10.1097\/IGC.0b013e318234f833_bb0055","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1200\/JCO.1992.10.9.1485","article-title":"Phase I trial of intraperitoneal taxol: a Gynecologic Oncology Group study","volume":"10","author":"Markman","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1097\/IGC.0b013e318234f833_bb0060","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1200\/JCO.1998.16.8.2620","article-title":"Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group Study","volume":"16","author":"Markman","year":"1998","journal-title":"J Clin Oncol."},{"key":"10.1097\/IGC.0b013e318234f833_bb0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ygyno.2006.06.026","article-title":"Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous cisplatin and paclitaxel","volume":"103","author":"Ozlos","year":"2006","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0b013e318234f833_bb0070","doi-asserted-by":"crossref","first-page":"4528","DOI":"10.1200\/JCO.2006.06.0376","article-title":"Intraperitoneal chemotherapy in ovarian cancer remains experimental","volume":"24","author":"Gore","year":"2006","journal-title":"J Clin Oncol."},{"key":"10.1097\/IGC.0b013e318234f833_bb0075","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1002\/1097-0142(19940315)73:6<1693::AID-CNCR2820730623>3.0.CO;2-0","article-title":"Evaluation of survival after second-line intraperitoneal cisplatin-based chemotherapy for advanced ovarian cancer","volume":"73","author":"Piver","year":"1994","journal-title":"Cancer."},{"key":"10.1097\/IGC.0b013e318234f833_bb0080","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1200\/JCO.1987.5.10.1607","article-title":"Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy","volume":"5","author":"Howell","year":"1987","journal-title":"J Clin Oncol."},{"key":"10.1097\/IGC.0b013e318234f833_bb0085","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1200\/JCO.1991.9.10.1801","article-title":"Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin","volume":"9","author":"Markman","year":"1991","journal-title":"J Clin Oncol."},{"key":"10.1097\/IGC.0b013e318234f833_bb0090","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1006\/gyno.1998.4973","article-title":"A phase II trial of intraperitoneal cisplatin and etoposide as consolidation therapy in patients with stage II-IV epithelial ovarian cancer following negative surgical assessment","volume":"69","author":"Barakat","year":"1998","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0b013e318234f833_bb0095","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ygyno.2003.10.002","article-title":"Efficacy of intraperitoneal cisplatin as consolidation therapy in patients with pathologic complete remission following front-line therapy for epithelial ovarian cancer. Consolidative intraperitoneal cisplatin in ovarian cancer","volume":"92","author":"Topuz","year":"2004","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0b013e318234f833_bb0100","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1200\/JCO.2002.20.3.694","article-title":"Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow-up","volume":"20","author":"Barakat","year":"2002","journal-title":"J Clin Oncol."},{"key":"10.1097\/IGC.0b013e318234f833_bb0105","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ygyno.2005.07.117","article-title":"Randomized trial of adjuvant intraperitoneal alpha-interferon in stage III ovarian cancer patients who have no evidence of disease after primary surgery and chemotherapy: an intergroup study","volume":"100","author":"Alberts","year":"2006","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0b013e318234f833_bb0110","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1136\/ijgc-00009577-200311001-00012","article-title":"Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy","volume":"13","author":"Piccart","year":"2003","journal-title":"Int J Gynecol Cancer."},{"key":"10.1097\/IGC.0b013e318234f833_bb0115","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1111\/IGC.0b013e3181a29dfe","article-title":"Phase II study of intraperitoneal carboplatin with intravenous paclitaxel in patients with suboptimal residual epithelial ovarian or primary peritoneal cancer","volume":"19","author":"Fujiwara","year":"2009","journal-title":"Int J Gynecol Cancer."}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24058328?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24058328?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T01:13:14Z","timestamp":1753233194000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24058328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S1048891X24058328"],"URL":"https:\/\/doi.org\/10.1097\/igc.0b013e318234f833","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intraperitoneal Chemotherapy for Recurrent Epithelial Ovarian Cancer Is Feasible With High Completion Rates, Low Complications, and Acceptable Patient Outcomes","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1097\/IGC.0b013e318234f833","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 by IGCS and ESGO","name":"copyright","label":"Copyright"}]}}